Cargando…
Telmisartan and cardioprotection
Cardiovascular risk reduction has been the target of several large clinical trials in the last decade. As the activation of the renin-angiotensin-aldosterone system (RAAS) plays a central role in the pathogenesis of atherosclerosis and cardiovascular disease, RAAS blockade has been suggested to be a...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225351/ https://www.ncbi.nlm.nih.gov/pubmed/22140319 http://dx.doi.org/10.2147/VHRM.S9447 |
_version_ | 1782217501500768256 |
---|---|
author | Akhrass, Philippe R McFarlane, Samy I |
author_facet | Akhrass, Philippe R McFarlane, Samy I |
author_sort | Akhrass, Philippe R |
collection | PubMed |
description | Cardiovascular risk reduction has been the target of several large clinical trials in the last decade. As the activation of the renin-angiotensin-aldosterone system (RAAS) plays a central role in the pathogenesis of atherosclerosis and cardiovascular disease, RAAS blockade has been suggested to be among the most efficient cardioprotective interventions, as revealed with the angiotensin converting enzyme (ACE) inhibitors trials. The angiotensin receptor blockers’ (ARBs) efficacy in lowering blood pressure has been very well established. Telmisartan is however the first ARB to show a promising role in reducing cardiovascular risk in high-risk patients. This article will highlight the role of telmisartan in cardioprotection, underlying specifically the results of two major randomized controlled trials: ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized AssessmeNt Study in aCE-iNtolerant subjects with cardiovascular Disease). |
format | Online Article Text |
id | pubmed-3225351 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-32253512011-12-02 Telmisartan and cardioprotection Akhrass, Philippe R McFarlane, Samy I Vasc Health Risk Manag Review Cardiovascular risk reduction has been the target of several large clinical trials in the last decade. As the activation of the renin-angiotensin-aldosterone system (RAAS) plays a central role in the pathogenesis of atherosclerosis and cardiovascular disease, RAAS blockade has been suggested to be among the most efficient cardioprotective interventions, as revealed with the angiotensin converting enzyme (ACE) inhibitors trials. The angiotensin receptor blockers’ (ARBs) efficacy in lowering blood pressure has been very well established. Telmisartan is however the first ARB to show a promising role in reducing cardiovascular risk in high-risk patients. This article will highlight the role of telmisartan in cardioprotection, underlying specifically the results of two major randomized controlled trials: ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized AssessmeNt Study in aCE-iNtolerant subjects with cardiovascular Disease). Dove Medical Press 2011 2011-11-15 /pmc/articles/PMC3225351/ /pubmed/22140319 http://dx.doi.org/10.2147/VHRM.S9447 Text en © 2011 Akhrass and McFarlane, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Akhrass, Philippe R McFarlane, Samy I Telmisartan and cardioprotection |
title | Telmisartan and cardioprotection |
title_full | Telmisartan and cardioprotection |
title_fullStr | Telmisartan and cardioprotection |
title_full_unstemmed | Telmisartan and cardioprotection |
title_short | Telmisartan and cardioprotection |
title_sort | telmisartan and cardioprotection |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225351/ https://www.ncbi.nlm.nih.gov/pubmed/22140319 http://dx.doi.org/10.2147/VHRM.S9447 |
work_keys_str_mv | AT akhrassphilipper telmisartanandcardioprotection AT mcfarlanesamyi telmisartanandcardioprotection |